Drug intelligence / Profile preview

influenza a h1n1 whole virus vaccine

Development stage: Approved
Lead developer: Sanofi Pasteur
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Influenza A H1N1 Whole Virus Vaccine is a vaccine designed to protect against the influenza A H1N1 virus strain. It is administered as an intramuscular injection and works by stimulating the immune system to produce antibodies against the H1N1 influenza virus. The vaccine contains inactivated (killed) H1N1 influenza virus components that cannot cause infection but can trigger an immune response.

Brand names: Panenza
Other names: Influenza A (H1N1) 2009 Monovalent Vaccine

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on influenza a h1n1 whole virus vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on influenza a h1n1 whole virus vaccine.

Explore the full profile